Sasinowska-Motyl M, Wiśniewska I, Gumułka W, Oszczapowicz I, Szelachowska M, Interewicz B
Department of Pharmacodynamics, School of Medicine, Warsaw, Poland.
Acta Pol Pharm. 1995 Sep-Oct;52(5):391-5.
Concentrations of cefuroxime [II] in blood of rats were measured 30 and 60 min. after administration of amorphous form possessing various particles size (ranging from 0.09 to 0.4 nm) and crystal form of 1-acethoxyethyl ester of cefuroxime [I]. In vitro the concentrations of [II] were measured 15 and 45 min. after application of [I]. HPLC method was used for cefuroxime estimation. Close correlation between the particles size of the amorphous [I] and the concentrations of [II] in vivo as well as in vitro was found, the particles with lover size possessed higher bioavailability. The cefuroxime front the crystal form of ester is poorly absorbed and the concentrations of [II] after its application were similar to those observed after of the bigest particles of amorphous form both in vivo and in vitro.
在给予具有各种粒径(范围为0.09至0.4纳米)的头孢呋辛[I]无定形形式和头孢呋辛1 - 乙酰氧基乙酯[I]的晶体形式后30分钟和60分钟,测量大鼠血液中头孢呋辛[II]的浓度。在体外,在应用[I]后15分钟和45分钟测量[II]的浓度。采用高效液相色谱法测定头孢呋辛。发现无定形[I]的粒径与体内外[II]的浓度之间存在密切相关性,粒径较小的颗粒具有较高的生物利用度。酯的晶体形式的头孢呋辛吸收较差,应用后[II]的浓度与体内外应用最大粒径的无定形形式后观察到的浓度相似。